Články a aktuality 2012 - 2018

Laboratory of Clinical Biochemistry (Unit for Cancer Research), Hospital Clinic, University of Barcelona, Spain, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

OBJECTIVE: The objective of this study was to evaluate tumor marker (TM) sensitivity and specificity in the differential diagnosis of patients with suspected signs of cancer.

PATIENTS AND METHODS:  We studied 4776 consecutive patients admitted in our Hospital with suspected cancer; 3281 patients had nonmalignant processes and 1495 had malignant disease. Determinations were considered positive for suspected malignancy when serum TM levels were higher than the cut-off found in a previous study (1).

RESULTS: There was a specificity of 98% in patients without malignancy, 72.2% of sensitivity in 1214 patients with epithelial malignancy (52.3% in patients with locally advanced tumors and 78.1% in patients with metastases). Sensitivity was 81.7% in 126 patients with cancer of cancer unknown primary site (CUP). TM were useful in the differential diagnosis between epithelial and non epithelial tumors, brain masses (metastases vs. primary tumors), or other paraneoplastic syndromes

CONCLUSIONS: TMs are useful as an aid in the evaluation of the risk of cancer of these patients with suspected cancer, and may be useful to reduce the hospitalization time, morbidity and the number of diagnostic tests required for diagnosis

This prezentation was supported by project Molekulární genetika nádorových a kardiovaskulárních chorob (CZ.1.07/2.3.00/20.0040)